Anixa Biosciences INC Form 4 insider transactions

Amit Kumar, Chief Executive Officer and a Director of Anixa Biosciences Inc, purchased 5,000 shares of common stock on July 31, 2026 for $3.47 per share.

Arnold M Baskies, a Director of Anixa Biosciences Inc, reported multiple transactions in common stock on July 27, 2026.

Amit Kumar, Chief Executive Officer and a Director of Anixa Biosciences Inc, purchased 5,000 shares of common stock on July 27, 2026 for $3.44 per share.

Amit Kumar, Chief Executive Officer and a Director of Anixa Biosciences Inc, purchased 3,188 shares of common stock on July 27, 2026 for $3.37 per share.

Amit Kumar, Chief Executive Officer and a Director of Anixa Biosciences Inc, purchased 3,000 shares of common stock on July 24, 2026 for $3.73 per share.

Amit Kumar, Chief Executive Officer and a Director of Anixa Biosciences Inc, purchased 5,000 shares of common stock on July 20, 2026 for $3.46 per share.

Lewis H Titterton Jr, a Director of Anixa Biosciences Inc, purchased 12,000 shares of common stock on July 20, 2026 for $3.47 per share.

Lewis H Titterton Jr, a Director of Anixa Biosciences Inc, purchased 2,797 shares of common stock on July 15, 2026 for $3.28 per share.

Amit Kumar, Chief Executive Officer and a Director of Anixa Biosciences Inc, purchased 5,000 shares of common stock on July 10, 2026 for $3.04 per share.

Anixa Biosciences Director Lewis H. Titterton Jr. reported the acquisition of 2,836 shares of common stock on June 16, 2026.

Anixa Biosciences CEO Amit Kumar acquired 21,000 shares of common stock on June 12, 2026, at a price of $2.50 per share.

Anixa Biosciences Director Arnold M. Baskies purchased 10,000 shares of common stock at $3.04 per share, increasing his direct beneficial ownership to 135,000 shares.

Anixa Biosciences director Lewis H. Titterton, Jr. was granted 25,000 employee stock options with an exercise price of $3.18, vesting monthly starting January 31, 2026.

Anixa Biosciences CEO Amit Kumar was granted 350,000 employee stock options with a future transaction date of January 5, 2026, vesting over 36 months.

Anixa Biosciences Director Emily Gottschalk was granted 25,000 employee stock options with an exercise price of $3.18, vesting monthly starting January 31, 2026.

Anixa Biosciences Inc. granted 175,000 employee stock options to President, COO & CFO Michael Catelani, vesting monthly over three years.

Anixa Biosciences director Arnold M. Baskies received a grant of 25,000 employee stock options with an exercise price of $3.18 per share.

Anixa Biosciences Director Lewis H. Titterton Jr. exercised 16,000 employee stock options at $2.92 per share, increasing his direct common stock holdings.

Anixa Biosciences CEO Amit Kumar exercised 200,000 stock options, acquiring shares and having a portion withheld for taxes and exercise costs.

Anixa Biosciences Director Lewis H. Titterton, Jr. acquired 10,000 shares of common stock for $3.08 per share, increasing his total beneficial ownership.

Anixa Biosciences CEO Amit Kumar purchased 5,000 shares of common stock at $3.16 per share, increasing his direct beneficial ownership.

Anixa Biosciences Inc. Director Arnold M. Baskies acquired 5,000 shares of common stock at $3.39 per share, increasing his beneficial ownership to 125,000 shares.

Anixa Biosciences Inc. Director Lewis H. Titterton Jr. purchased 10,000 shares of common stock at $3.14 per share, increasing his direct beneficial ownership to 943,334 shares.

Anixa Biosciences CEO Amit Kumar has reported the purchase of 5,000 shares of common stock at $3.15 per share, increasing his direct beneficial ownership to 574,925 shares.

Anixa Biosciences' Chief Executive Officer, Amit Kumar, has acquired an additional 10,000 shares of the company's common stock at $2.85 per share, increasing his total beneficial ownership to 569,925 shares.

Anixa Biosciences director Arnold M. Baskies purchased 5,000 shares of common stock at $2.82 per share on January 28, 2025.

Anixa Biosciences director Lewis H. Titterton Jr. acquired 3,000 shares of common stock through open market purchases on January 23rd and 24th, 2025.

Anixa Biosciences director Lewis H. Titterton Jr. purchased 2,000 shares of common stock at $3.01 per share on January 22, 2025.

Anixa Biosciences director, Lewis H. Titterton Jr., purchased 6,000 shares of common stock at $2.59 per share on January 21, 2025.

Anixa Biosciences director Lewis H. Titterton Jr. purchased 10,000 shares of common stock at $2.57 per share on January 17, 2025.